

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT
HUIHENG BIOPHARMACEUTICAL'S DRUG
MECOBALAMIN TABLETS APPROVED FOR
MARKETING BY NMPA

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the mecobalamin tablets (specification: 0.5mg), a peripheral neuropathy drug developed by the Group’s non-wholly owned subsidiary, Huisheng Biopharmaceutical Co., Ltd. (“**Huisheng Biopharmaceutical**”), has obtained drug registration approval from the National Medical Products Administration (the “**NMPA**”) of the People’s Republic of China (“**China**”), and is deemed to have passed the consistency evaluation on quality and efficacy of generic drugs. Mecobalamin tablet is Huisheng Biopharmaceutical’s first drug approved for marketing, and also the first anti diabetes complication drug approved for marketing, which remarks the new milestone of Huisheng Biopharmaceutical’s anti diabetes complication drugs from research and development to commercialization.

Mecobalamin is an endogenous coenzyme B12 that is not metabolised by the liver and does not require biotransformation and can directly play an active role. It is used clinically in the treatment of various peripheral neurological conditions such as neuralgia, facial paralysis, neuritis and neurological disorders. It is also used in the treatment of diabetic peripheral neuropathy (DPN). The Diagnostic and Therapeutic Consensus for Diabetic Peripheral Neuropathy recommends metacobalamin for the treatment of DPN neurotrophic repair.

The incidence rate of DPN among diabetes patients is as high as 60%, which is a very common chronic complication of diabetes. According to the latest report of IDF, China had about 140 million diabetes patients in 2021, according to this calculation, there are about 84 million patients with DPN in China. Mecobalamin tablet is a Category B drug under the National Reimbursement Drug List (2022 Edition). According to IMS data, the procurement of mecobalamin tablets by China sample hospitals in 2022 exceeded RMB 1 billion. With the growth of the diabetes market, mecobalamin is expected to further expand.

About Huisheng Biopharmaceutical

Huisheng Biopharmaceutical is a biopharmaceutical company under Sihuan Pharmaceutical, a large domestic pharmaceutical and medical aesthetics group, focusing on the areas of diabetes and complications. After eight years of construction and development, Huisheng Biopharmaceutical has become one of the few company in China that has achieved full product coverage in the field of diabetes and related complications, and integrated the whole industrial chain of R&D, production and sales. the company currently has a world-class R&D team of more than 200 people with rich experience in diabetes drug research and development. At present, it has more than 40 products in the research product pipeline of diabetes and complications, covering a full range of second-, third-, and new-generation insulin (covering basic, premixed and quick-acting etc.), innovative drugs with the latest mechanism, such as SGLT-2i, GLP-1a, and other hypoglycemic drugs and complication drugs. Huisheng Biopharmaceutical is committed to providing full-process, all-round integrated treatment solutions for diabetic patients, serving patients and making health easier.

About Sihuan Pharmaceutical

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group’s latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 1 June 2023

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.